Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Screening for Hereditary Cancer Syndromes.

Radiologic clinics of North America·2026
Same author

Current Update on Nomenclature, Diagnosis, and Management of Metabolic Dysfunction-associated Steatotic Liver Disease: Radiologists' Perspective.

Radiographics : a review publication of the Radiological Society of North America, Inc·2025
Same author

Update on Tumor Genetics and Molecular Biology of Selected Renal Cell Carcinomas: Implications on Diagnosis and Management.

Seminars in roentgenology·2025
Same author

Update on Pathologic Conditions, Imaging Findings, Prevention, and Management of Human Papillomavirus-related Neoplasms.

Radiographics : a review publication of the Radiological Society of North America, Inc·2024
Same author

Tumefactive Nonneoplastic Proliferative Pseudotumors of the Kidneys and Urinary Tract: CT and MRI Findings with Histopathologic Correlation.

Radiographics : a review publication of the Radiological Society of North America, Inc·2023
Same author

Classical Hematology Referrals at an National Cancer Institute-Designated Cancer Center: Lessons Learned.

JCO oncology practice·2023

Related Experiment Video

Updated: Jun 10, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Tumor response evaluation in oncology: current update.

Alampady Krishna Prasad Shanbhogue1, Anand B Karnad, Srinivasa R Prasad

  • 1Department of Radiology, University of Texas HSC at San Antonio, San Antonio, TX 78229, USA. shanbhogue@uthscsa.edu

Journal of Computer Assisted Tomography
|July 27, 2010
PubMed
Summary
This summary is machine-generated.

Evaluating cancer treatment response requires standardized tumor measurement. This review covers updated guidelines like RECIST 1.1 for consistent oncology trial assessments.

Related Experiment Videos

Last Updated: Jun 10, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Area of Science:

  • Oncology
  • Medical Imaging
  • Clinical Trials

Background:

  • Accurate quantification of tumor burden is crucial for evaluating chemotherapy effectiveness in oncology.
  • Standardized criteria for tumor measurement are needed to ensure uniformity and comparability across clinical trials.
  • Previous response assessment methods include bidimensional (WHO) and unidimensional (RECIST) measurements.

Purpose of the Study:

  • To provide a comprehensive review of tumor response evaluation guidelines.
  • To highlight recent updates in response assessment criteria, including RECIST 1.1.
  • To discuss how updated guidelines address limitations of prior methods and incorporate advances in imaging.

Main Methods:

  • Review of existing literature on tumor response evaluation criteria.
  • Analysis of the evolution from WHO criteria to RECIST and RECIST 1.1.
  • Discussion of measurement techniques and their impact on treatment response assessment.

Main Results:

  • RECIST 1.1 criteria have been recently published, offering an updated approach to tumor response assessment.
  • The updated guidelines aim to overcome limitations of previous criteria.
  • Recent advances in imaging techniques are incorporated into the new guidelines.

Conclusions:

  • Standardized tumor response evaluation is essential for reliable oncology trial outcomes.
  • RECIST 1.1 represents a significant update in solid tumor assessment methodology.
  • Adoption of updated guidelines facilitates consistent and comparable evaluation of cancer treatment efficacy.